Book a 68Ga-DOTANOC Whole Body PET-CT Scan at Molecular Diagnostics and Therapy, an NABL- and NABH-accredited diagnostic centre that offers state-of-the-art nuclear medicine, radiology, and pathology services. A specialized PET-CT scan using Gallium-68 DOTANOC (68Ga-DOTANOC) is used to image conditions that increase somatostatin receptor expression, such as NETs. Both PET and CT are functional, but CT gives information about the anatomy. We have experienced nuclear medicine specialists employing state-of-the-art PET-CT imaging and proper radiation safety guidelines for accurate scanning and report writing.
About 68Ga-DOTANOC Whole BodyPET-CT
68Ga-DOTANOC Whole Body PET-CT Scan detects tissue and tumor presence that express somatostatin receptors. The radiotracer binds to these receptors, and regions where increased uptake of the radiotracer is seen on PET imaging. Molecular Diagnostics and Therapy utilizes cutting-edge PET-CT technology to gain a functional and anatomical image of the entire body.
What is a 68Ga-DOTANOC Whole Body PET-CT?
Whole Body PET-CT with 68Ga-DOTANOC involves the injection of a small amount of radioactive 68Ga-DOTANOC tracer into the bloodstream. Following the injection, the patient lies on the PET-CT scanner table. PET shows greater somatostatin receptor activity, and the CT shows anatomical information. The superimposed images facilitate the doctor's evaluation of the location and extent of disease.
Common Reasons for 68Ga-DOTATATE Whole Body PET-CT
Detection of neuroendocrine tumors
Staging of neuroendocrine tumors
Localization of primary tumors
Detection of metastatic disease
Evaluation of somatostatin receptor-positive lesions
Treatment planning for receptor-targeted therapies
Monitoring selected neuroendocrine tumors
Evaluation of suspected recurrent disease
Conditions Evaluated
Neuroendocrine Tumors
Helps detect and localize tumors that express somatostatin receptors.
Metastatic Neuroendocrine Tumors
Helps identify the spread of receptor-positive disease to different parts of the body.
Unknown Primary Tumors
May help locate the primary site when neuroendocrine tumor metastasis is suspected.
Recurrent Disease
Supports evaluation for recurrent or persistent receptor-positive tumor activity.
Treatment Planning
Provides information about somatostatin receptor expression that may assist in considering receptor-targeted therapies.
Who Should Consider This Scan?
Your doctor may recommend a 68Ga-DOTANOC Whole Body PET-CT Scan if you:
Have a confirmed or suspected neuroendocrine tumor
Need staging of a neuroendocrine malignancy
Require evaluation for metastatic disease
Have suspected recurrent neuroendocrine tumor
Need localization of an unknown primary tumor
Require assessment of somatostatin receptor expression
Benefits of 68Ga-DOTATATEWhole BodyPET CT
Provides whole-body functional imaging
Detects somatostatin receptor-positive lesions
Combines PET functional information with CT anatomy
Helps identify primary and metastatic disease
Supports staging and treatment planning
Useful for evaluating selected receptor-targeted treatment options
Why Choose Molecular Diagnostics and Therapy?
Experienced Nuclear Medicine Specialists
Advanced PET-CT Imaging Technology
NABL & NABH Accredited Diagnostic Centre
Accurate and reliable reporting
Appropriate radiation safety protocols
Affordable and transparent pricing
Comprehensive Nuclear Medicine, Radiology, and Pathology services under one roof
Book your 68Ga-DOTANOC Whole Body PET-CT.
Book your 68Ga–DOTANOC Whole Body PET-CT scan at Molecular Diagnostics and Therapy. Our high-quality nuclear medicine care and services enable doctors to assess neuroendocrine tumors, metastatic disease, recurrence, and somatostatin receptor expression.
Test information: Fasting is not required.
Reporting: Within 24 hours.
Fasting may be required depending on the scan protocol. Follow the fasting instructions provided by the Nuclear Medicine team.
Stay adequately hydrated before and after the scan unless your doctor advises otherwise.
Inform the Nuclear Medicine team about any current medications, ongoing treatments, or relevant medical conditions.
If you are pregnant, may be pregnant, or are breastfeeding, inform the Nuclear Medicine team before the scan.
Carry previous PET-CT scans, CT/MRI reports, biopsy reports, treatment records, or other relevant medical documents, if available.
Follow all instructions regarding food, fluids, medications, and activity provided before the examination.
Do not stop or change any prescribed medication unless specifically advised by your doctor.
Follow the radiation-safety and post-scan instructions provided by the Nuclear Medicine team.
जांच की प्रक्रिया के अनुसार खाली पेट रहना आवश्यक हो सकता है। न्यूक्लियर मेडिसिन टीम द्वारा बताए गए समय तक भोजन न करने के निर्देशों का पालन करें।
डॉक्टर द्वारा अन्यथा न बताए जाने पर जांच से पहले और बाद में पर्याप्त मात्रा में पानी पिएं।
अपनी वर्तमान दवाइयों, चल रहे उपचार और किसी भी संबंधित स्वास्थ्य समस्या के बारे में न्यूक्लियर मेडिसिन टीम को जानकारी दें।
यदि आप गर्भवती हैं, गर्भवती होने की संभावना है या स्तनपान करा रही हैं, तो जांच से पहले न्यूक्लियर मेडिसिन टीम को अवश्य बताएं।
उपलब्ध होने पर पिछली पीईटी-सीटी, सीटी, एमआरआई, बायोप्सी रिपोर्ट, उपचार संबंधी दस्तावेज या अन्य चिकित्सकीय अभिलेख साथ लेकर आएं।
जांच से पहले भोजन, पानी, दवाइयों और अन्य गतिविधियों से संबंधित दिए गए सभी निर्देशों का पालन करें।
डॉक्टर की सलाह के बिना कोई भी निर्धारित दवा बंद न करें और उसकी खुराक में बदलाव न करें।
जांच के बाद न्यूक्लियर मेडिसिन टीम द्वारा दिए गए विकिरण सुरक्षा और जांच के बाद की सावधानियों से संबंधित निर्देशों का पालन करें।
The patient is registered, and relevant clinical details and previous medical records are reviewed.
A small amount of 68Ga-DOTANOC radiotracer is administered intravenously under appropriate supervision.
The patient is given an appropriate uptake period to allow the tracer to distribute through the body and bind to areas expressing somatostatin receptors.
The patient is positioned comfortably on the PET-CT scanner table.
PET imaging is performed to assess the distribution and uptake of the radiotracer throughout the body.
CT imaging is performed to provide detailed anatomical information and help accurately localize areas of tracer uptake.
PET and CT images are combined to provide functional and anatomical information for clinical evaluation.
The images are assessed for areas of increased or abnormal tracer uptake that may correspond to somatostatin receptor-positive lesions.
Relevant clinical history, previous imaging, biopsy findings, and treatment history may be considered during interpretation.
Appropriate radiation-safety measures and imaging quality-control protocols are followed throughout the examination.
The scan is generally well tolerated, although the total procedure time may vary according to the clinical protocol.
The images are reviewed by experienced Nuclear Medicine Specialists before the final report is prepared.
* For details, please see service-related policies
Disclaimer: The information provided on this page is for educational and informational purposes only.
It is not intended to replace professional medical advice, diagnosis, or treatment.
Always consult a qualified healthcare professional for advice regarding your individual health condition or treatment.